Search results for "kinetics"

showing 10 items of 2224 documents

Differential effect of insulin and epidermal growth factor on the mRNA translocation system and transport of specific poly(A+) mRNA and poly(A-) mRNA…

1990

The efficiency of efflux of rapidly labeled poly(A)-containing mRNA from isolated rat liver nuclei was found to be modulated by insulin and epidermal growth factor (EGF) in a biphasic but opposite way. At physiological concentrations (10 pM insulin and 1 pM EGF), maximal stimulation of the transport rate by insulin (to 137%) and maximal inhibition by EGF (to 69%) were obtained; at higher concentrations (greater than 100 pM and greater than 10 pM, respectively), the amount of poly(A)-containing mRNA released into the postnuclear supernatant was nearly identical with the level found in untreated nuclei (= 100%). Using mRNA entrapped into closed nuclear envelope (NE) vesicles as a model system…

MaleNuclear Envelopemedicine.medical_treatmentPhosphoprotein phosphatase activityBiologyBiochemistryDephosphorylationAdenosine TriphosphateEpidermal growth factormedicineCyclic AMPMRNA transportAnimalsInsulinRNA MessengerBinding sitePhosphorylationCyclic GMPCell NucleusMessenger RNAEpidermal Growth FactorInsulinBiological TransportRats Inbred StrainsBlotting NorthernNucleoside-TriphosphataseMolecular biologyPhosphoric Monoester HydrolasesRatsKineticsPhosphorylationPoly ABiochemistry
researchProduct

Fatty acid amide hydrolase controls mouse intestinal motility in vivo.

2005

Background & Aims: Fatty acid amide hydrolase (FAAH) catalyzes the hydrolysis both of the endocannabinoids (which are known to inhibit intestinal motility) and other bioactive amides (palmitoylethanolamide, oleamide, and oleoylethanolamide), which might affect intestinal motility. The physiologic role of FAAH in the gut is largely unexplored. In the present study, we evaluated the possible role of FAAH in regulating intestinal motility in mice in vivo. Methods: Motility was measured by evaluating the distribution of a fluorescent marker along the small intestine; FAAH messenger RNA (mRNA) levels were analyzed by reverse-transcription polymerase chain reaction (RT-PCR); endocannabinoid level…

MaleOleamideCannabinoid receptormedicine.drug_classMotilityPharmacologyBiologyAmidohydrolaseschemistry.chemical_compoundOleoylethanolamideMiceFatty acid amide hydrolaseIntestine SmallmedicineAnimalsIntestine LargeRNA MessengerGastrointestinal TransitPalmitoylethanolamideMice Inbred ICRHepatologyReverse Transcriptase Polymerase Chain ReactionGastroenterologyReceptor antagonistEndocannabinoid systemKineticsnervous systemBiochemistrychemistrylipids (amino acids peptides and proteins)Gastrointestinal Motilitypsychological phenomena and processesGastroenterology
researchProduct

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-…

2009

Abstract Background This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m…

MaleOncologymedicine.medical_specialtyMaximum Tolerated DoseCombination therapyColorectal cancerLeucovorinCetuximabAntibodies Monoclonal HumanizedIrinotecanImmunoenzyme TechniquesFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTissue DistributionneoplasmsAgedDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseasedigestive system diseasesSurgeryErbB ReceptorsSurvival RateIrinotecanTreatment OutcomeOncologyPharmacodynamicsFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs

2021

We present a generic workflow combining physiology-based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepatic circulation of bile acids were obtained from an in vitro assay mimicking 14 days of repeated drug administration for 10 marketed drugs. These changes in gene expression over time were contextualized in a physiology-based bile acid model of glycochenodeoxycholic acid. The simulated drug-induced response in bile acid concentrations was then scaled with the applied drug doses to calculate the cholestatic potential for each compound. A ranking of the cholest…

MalePHARMACOKINETICSAZATHIOPRINEAzathioprineBioinformatics030226 pharmacology & pharmacyWorkflowchemistry.chemical_compound0302 clinical medicinePARACETAMOLPharmacology (medical)Enterohepatic circulationmedia_common0303 health sciencesCholestasisBile acidMiddle Aged3. Good healthBenchmarkingLiverPharmaceutical PreparationsSINGLEDrug developmentFemaleVALPROATEmedicine.drugAdultDrugDrug-Related Side Effects and Adverse ReactionsDICLOFENAC SODIUMmedicine.drug_classmedia_common.quotation_subjectModels BiologicalYoung Adult03 medical and health sciencesCholestasisPharmacokineticsSpheroids CellularmedicineGlycochenodeoxycholic acidAnimalsHumansddc:610030304 developmental biologyPharmacologybusiness.industrymedicine.diseasechemistryACETAMINOPHENbusinessClinical Pharmacology & Therapeutics
researchProduct

Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's dise…

2018

[EN] Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist) and rasagiline (RAS; MAO-B inhibitor) in vitro and in vivo. Passive permeation of PRAM and RAS (20 mM each) across porcine skin after 6 h was 15.7 +/- 1.9 and 16.0 +/- 2.9 mu g/cm(2), respectively. Co-iontophoresis at 0.15, 0.3 and 0.5 mA/cm(2) resulted in statistically significant increases in delivery of PRAM and RAS; at 0.5 mA/cm(2), cumulative permeation of PRAM and RAS was 61…

MaleParkinson's diseaseSwineChemistry PharmaceuticalSkin AbsorptionPharmaceutical SciencePharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDopamine agonistPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePramipexolePharmacokineticsIn vivomedicineAnimalsHumansBenzothiazolesMAO-B inhibitorRats WistarTransdermalSkinRasagilinePramipexoleIontophoresisDopamine agonistPatient complianceParkinson DiseaseGeneral MedicineIontophoresismedicine.diseaseRatschemistryIndansPolypharmacyElectroosmosisTransdermal030217 neurology & neurosurgeryBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Analysis of human dysplastic haematopoiesis in long-term bone marrow culture

1989

In this paper we have analysed the behaviour of myelodysplastic marrow in a long-term bone marrow liquid culture system (LTBMC) from eleven patients with myelodysplastic syndromes with regard to cellularity, day-7 and day-14 CFU-GM growth, cluster formation, adherent cells and CFU-F formation. An altered CFU-GM pattern was found in 64% of cases at diagnosis, while normal growth was seen in the remaining cases, all of which were affected by refractory anaemia. The levels of CFU-GM, as well as cellularity, were reduced in myelodysplastic marrows compared to normal controls over the whole duration of LTBMCs. Cases with a normal CFU-GM level at diagnosis also showed pathological behaviour when …

MalePathologymedicine.medical_specialtyCFU-GMBiologyColony-Forming Units AssayInternal medicineCell AdhesionmedicineHumansPathologicalAgedErythroid Precursor CellsHematologyMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseHematopoiesisKineticsHaematopoiesismedicine.anatomical_structureCell cultureMyelodysplastic SyndromesBone marrow cultureBone marrowBlut
researchProduct

Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness.

2012

Hepatocellular carcinoma (HCC) management takes into account clinical and radiological findings, such as tumor stage, hepatic functional status and clinical symptoms. It is necessary to evaluate the number, size and location of the lesions. However, lesion aggressiveness is not considered in this therapeutic workflow, although the biology and the growth rate of the lesions have an important impact on survival. The aim of this work was to establish if the quantitative pharmacokinetic assessment of dynamic contrast-enhanced magnetic resonance images of HCC can separate lesions with different microvascular properties and biological evolution. Forty five patients with HCC and dynamic contrast-e…

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularPharmacokinetic modelingContrast MediaKaplan-Meier EstimateLesionCapillary PermeabilityPharmacokineticsTumor stagemedicineBiomarkers TumorCluster AnalysisHumansAgedHepatologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyMagnetic resonance imagingBiological evolutionMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingHepatocellular carcinomaDisease ProgressionFunctional statusFemalemedicine.symptomNeoplasm GradingbusinessExpert review of gastroenterologyhepatology
researchProduct

Non-linear Intestinal Absorption Kinetics of Cefadroxil in the Rat

1989

Abstract Absorption of Cefadroxil in a selective intestinal absorption area (the proximal third of the small intestine) of the anaesthetized rat, at seven initial perfusion concentrations, ranging from 0·01 to 10·0 mg mL−1, is shown to be a non-linear transport mechanism. With the aid of computer-fitting procedures based on differential and integrated forms of Michaelis-Menten equation, Vm and Km values of 36·7–37·3 mg h−1 and 12·0–13·0 mg, respectively, were found. The statistical parameters were better than those obtained both for first-order and for combined Michaelis-Menten and first-order kinetics. There is no evidence for substantial passive diffusion processes. The results reported h…

MalePharmacologyAbsorption (pharmacology)ChromatographyChemistryDiffusionKineticsCefadroxilPharmaceutical ScienceRats Inbred StrainsIntestinal absorptionSmall intestineRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionPharmacokineticsBiochemistryIntestine SmallCefadroxilmedicineAnimalsPerfusionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.

1979

The interaction of phenylbutazone with the enantiomers and racemic [ 3 H]phenprocoumon was studied in male inbred Wistar-Lewis rats following a single i.v. dose of the three forms of phenprocoumon and chronic oral treatment with phenylbutazone (average plasma concentration of about 60 Μg/ml). Phenylbutazone augmented the anticoagulant effect of R(+), S(−), and R, S (±) phenprocoumon to a similar extent. The free fraction of drug in the plasma of the enantiomers and racemic phenprocoumon increased in the presence of phenylbutazone. However, the rate of elimination of total drug from plasma and liver and the distribution between liver and plasma of all three forms of phenprocoumon remained ne…

MalePharmacologyPhenprocoumonElimination rate constantPhenylbutazonemedicineDistribution (pharmacology)AnimalsPharmacology (medical)Drug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsVolume of distributionChemistryAnticoagulantsStereoisomerism4-HydroxycoumarinsDrug interactionRatsKineticsLiverPhenylbutazoneFree fractionPhenprocoumonProthrombinEnantiomermedicine.drugJournal of pharmacokinetics and biopharmaceutics
researchProduct

Phenytoin-induced glutathione depletion in rat peripheral nerve

1995

Abstract Administration of high doses (150–250 mg/kg body weight) of phenytoin (DPH) promote a 40% decrease in glutathione (GSH) content of rat sciatic nerve. This DPH-induced GSH depletion is accompanied with an electrophysiological impairment of peripheral neuromuscular function. H7 (20 mg/kg body weight IP, 30 min prior to DPH), a protein kinase C inhibitor, was able to prevent the DPH-induced GSH depletion only at the lower DPH dose used. This same inhibitor completely prevented the electrophysiological impairment at the lower DPH dose, and only partially at the higher DPH dose used. These results confirm the hypothesis of a DPH-dependent activation of PKC (that might be triggered by, o…

MalePhenytoinAntioxidantmedicine.medical_treatmentAction PotentialsIn Vitro TechniquesPharmacologymedicine.disease_causeBiochemistryPiperazineschemistry.chemical_compound1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinePhysiology (medical)polycyclic compoundsmedicineAnimalsEnzyme InhibitorsRats WistarMuscle SkeletalEvoked PotentialsProtein Kinase CProtein kinase CMotor NeuronsAnalysis of Variancetechnology industry and agricultureNeurotoxicityGlutathioneIsoquinolinesmedicine.diseaseGlutathioneSciatic NerveRatsKineticschemistryBiochemistryPhenytoinAnticonvulsantslipids (amino acids peptides and proteins)Sciatic nerveOxidative stressIntracellularmedicine.drugFree Radical Biology and Medicine
researchProduct